These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26424837)

  • 1. Biologic efficacy optimization--a step towards personalized medicine.
    Kiely PD
    Rheumatology (Oxford); 2016 May; 55(5):780-8. PubMed ID: 26424837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
    Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.
    Favalli EG; Biggioggero M; Marchesoni A; Meroni PL
    Rheumatology (Oxford); 2014 Sep; 53(9):1664-8. PubMed ID: 24729445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice.
    Álvaro-Gracia JM; Fernández-Nebro A; García-López A; Guzmán M; Blanco FJ; Navarro FJ; Bustabad S; Armendáriz Y; Román-Ivorra JA;
    Reumatol Clin; 2014; 10(2):94-100. PubMed ID: 24099961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
    Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
    Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review.
    Gialouri CG; Pappa M; Evangelatos G; Nikiphorou E; Fragoulis GE
    Autoimmun Rev; 2023 Jul; 22(7):103357. PubMed ID: 37150489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
    Tanaka Y; Hirata S
    Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.
    Shan J; Zhang J
    Joint Bone Spine; 2019 Mar; 86(2):173-183. PubMed ID: 29635017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
    Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK
    Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis.
    Emery P; Sebba A; Huizinga TW
    Ann Rheum Dis; 2013 Dec; 72(12):1897-904. PubMed ID: 23918035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential use of biologic therapy in rheumatoid arthritis.
    Buch MH
    Curr Opin Rheumatol; 2010 May; 22(3):321-9. PubMed ID: 20190641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination therapy using methotrexate with DMARDs or biologics--current status].
    Krüger K
    Z Rheumatol; 2011 Feb; 70(2):114-22. PubMed ID: 21267733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis.
    Rau R
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S58-64. PubMed ID: 21044435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.
    Manders SH; Kievit W; Adang E; Brus HL; Moens HJ; Hartkamp A; Hendriks L; Brouwer E; Visser H; Vonkeman HE; Hendrikx J; Jansen TL; Westhovens R; van de Laar MA; van Riel PL
    Arthritis Res Ther; 2015 May; 17(1):134. PubMed ID: 25997746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis.
    Ruderman EM
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S29-32. PubMed ID: 24219038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
    Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge EM; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
    Rheumatology (Oxford); 2016 Feb; 55(2):230-6. PubMed ID: 26316581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.